ERBB2 and biliary tract cancer: A 2021 analysis of 39 patients with HER-2 positive metastatic biliary tract cancers who were treated with trastuzumab plus pertuzumab while enrolled in the phase II My Pathway umbrella study found an ORR of 23% [37].